|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
With the business potentially at an important milestone, we thought we'd take a closer look at Sarepta Therapeutics...
Biotechs that utilize gene editing -- a set of techniques allowing scientists to modify an organism's DNA -- have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).
There are many such corporations to consider on the market, but let's examine two: Guardant Health (NASDAQ: GH) and Sarepta Therapeutics (NASDAQ: SRPT). Progress in cancer research is always important as cancer is a leading cause of death worldwide. Guardant Health focuses on developing liquid biopsies -- tests that help detect signs of cancer from blood samples.